Table 1.
Demographic and clinical characteristics of convenience sample of MDR TB patients in the United States, 2012–2016 (N = 13).
| Patient characteristics | n, median (%, IQR) |
|---|---|
| Sex, male | 6 (46%) |
| Age, years | 51 (28–57) |
| Previous TB treatment with second-line drugs | 2 (15%) |
| Expert consultation obtained | 13 (100%) |
| Duration of treatment with second-line injectable, daysa | 216 (203–252) |
| Number of drugs in initial MDR TB treatment regimen | 6 (5–6) |
| Number of drugs ever used for treatment MDR TB | 6 (6–7) |
| Number patients experiencing side effect leading to a change in medication | 6 (46%) |
| Number patients experiencing side effect at the end of treatment | 8 (61.5%) |
| Number patients received surgery to treat MDR TB | 1 (8%) |
| Number hospitalized related to TB | 8 (61.5%) |
Note: IQR = interquartile range, MDR = multidrug resistant that is resistant to at least isoniazid or rifampin.
a
Calculated using the second-line injectable stop date and MDR TB treatment start date.